|
GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
US6319897B1
(en)
|
1996-03-13 |
2001-11-20 |
John D. Lambris |
Peptides which inhibit complement activation
|
|
AU7808198A
(en)
|
1997-06-03 |
1998-12-21 |
Biocryst Pharmaceuticals, Inc. |
Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
|
|
NZ507760A
(en)
|
1998-03-26 |
2002-10-25 |
Japan Tobacco Inc |
Amide derivatives and nociceptin antagonists
|
|
KR100818845B1
(ko)
|
1998-09-09 |
2008-04-01 |
메타베이시스 테라퓨틱스, 인크. |
신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
|
|
KR20000047461A
(ko)
*
|
1998-12-29 |
2000-07-25 |
성재갑 |
트롬빈 억제제
|
|
JP4489976B2
(ja)
|
1999-04-09 |
2010-06-23 |
ビーエーエスエフ ソシエタス・ヨーロピア |
補体プロテアーゼの低分子インヒビター
|
|
AU6868900A
(en)
|
1999-09-03 |
2001-04-10 |
Ajinomoto Co., Inc. |
Novel processes for preparing oxazepine derivatives
|
|
US7193065B2
(en)
|
2001-07-13 |
2007-03-20 |
Roche Diagnostics Operations, Inc. |
Protease inhibitor conjugates and antibodies useful in immunoassay
|
|
US7528165B2
(en)
|
2001-12-13 |
2009-05-05 |
National Health Research Institutes |
Indole compounds
|
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
|
WO2004007501A1
(en)
|
2002-07-16 |
2004-01-22 |
Amura Therapeutics Limited |
Biologically active compounds
|
|
PT1549333E
(pt)
|
2002-09-20 |
2012-01-03 |
Univ Pennsylvania |
Análogos de compstatina com actividade melhorada
|
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
|
WO2004045518A2
(en)
|
2002-11-15 |
2004-06-03 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
|
AU2003902946A0
(en)
|
2003-06-12 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
BRPI0506629A
(pt)
|
2004-02-10 |
2007-05-02 |
Univ Colorado |
inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
|
|
RU2393154C2
(ru)
|
2004-03-24 |
2010-06-27 |
Йерини Аг |
Новые соединения для ингибирования ангиогенеза и их применение
|
|
PL1755616T3
(pl)
|
2004-04-08 |
2014-10-31 |
Eye Co Pty Ltd |
Leczenie mineralokortykoidami retinopatii wysiękowej
|
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
|
WO2006012373A2
(en)
|
2004-07-20 |
2006-02-02 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
KR20080002832A
(ko)
|
2005-03-16 |
2008-01-04 |
얀센 파마슈티카 엔.브이. |
보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
CN102977191B
(zh)
|
2005-11-28 |
2016-08-10 |
宾夕法尼亚州大学理事会 |
有效的c3补体抑制素类似物
|
|
CA2633541A1
(en)
|
2005-12-12 |
2007-06-21 |
Genelabs Technologies, Inc. |
N-(6-membered aromatic ring)-amido anti-viral compounds
|
|
US20090220508A1
(en)
|
2006-03-15 |
2009-09-03 |
Alexion Pharmaceuticals, Inc. |
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
|
|
JPWO2008047831A1
(ja)
|
2006-10-17 |
2010-02-25 |
協和発酵キリン株式会社 |
Ｊａｋ阻害剤
|
|
RS51644B
(sr)
*
|
2007-01-10 |
2011-10-31 |
Irm Llc. |
Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
|
|
JP5070067B2
(ja)
|
2007-01-15 |
2012-11-07 |
参天製薬株式会社 |
ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
|
|
HUE026001T2
(en)
|
2007-02-05 |
2016-04-28 |
Apellis Pharmaceuticals Inc |
Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
|
|
US8921523B2
(en)
|
2007-12-11 |
2014-12-30 |
Glaxo Group Limited |
Humanized anti-beta-amyloid antibodies
|
|
AU2008339917B2
(en)
|
2007-12-24 |
2013-02-07 |
Tibotec Pharmaceuticals |
Macrocyclic indoles as hepatitis C virus inhibitors
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
AU2010208046B2
(en)
|
2009-01-29 |
2014-10-02 |
Forsight Vision4, Inc. |
Posterior segment drug delivery
|
|
CA2760839C
(en)
|
2009-05-01 |
2019-02-12 |
The Trustees Of The University Of Pennsylvania |
Modified compstatin with peptide backbone and c-terminal modifications
|
|
WO2010135717A2
(en)
|
2009-05-21 |
2010-11-25 |
Potentia Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
|
EP2490026A4
(en)
|
2009-10-16 |
2013-08-21 |
Mochida Pharm Co Ltd |
MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE
|
|
CA2795311A1
(en)
|
2009-11-05 |
2011-05-12 |
Taligen Therapeutics, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
|
EA030141B1
(ru)
|
2009-12-31 |
2018-06-29 |
Хатчисон Медифарма Лимитед |
Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
|
|
AU2011239966B2
(en)
|
2010-04-16 |
2014-05-08 |
Ac Immune S.A. |
Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
|
|
WO2011163394A2
(en)
|
2010-06-22 |
2011-12-29 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
US20130324482A1
(en)
|
2010-07-09 |
2013-12-05 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
|
|
PT2661433T
(pt)
|
2011-01-04 |
2017-10-24 |
Novartis Ag |
Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
|
|
EP2694521B1
(en)
|
2011-04-07 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
|
MX356528B
(es)
|
2011-05-11 |
2018-06-01 |
Apellis Pharmaceuticals Inc |
Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
|
|
JP6198721B2
(ja)
|
2011-05-27 |
2017-09-20 |
アキリオン ファーマシューティカルズ，インコーポレーテッド |
Ｈｃｖ感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン
|
|
EP2739144A4
(en)
|
2011-06-20 |
2015-04-01 |
Alzheimer S Inst Of America Inc |
COMPOUNDS AND ITS THERAPEUTIC USE
|
|
EP3524258B1
(en)
|
2011-06-22 |
2025-10-01 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US20130035392A1
(en)
|
2011-08-01 |
2013-02-07 |
Mcgeer Patrick L |
Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
|
|
CA2847862C
(en)
|
2011-09-07 |
2021-01-12 |
The Trustees Of The University Of Pennsylvania |
Compstatin analogs with improved pharmacokinetic properties
|
|
CN111700879A
(zh)
|
2012-05-03 |
2020-09-25 |
卡拉制药公司 |
显示提高的粘膜转移的药物纳米粒子
|
|
US9056874B2
(en)
|
2012-05-04 |
2015-06-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
BR112014031522A2
(pt)
|
2012-06-18 |
2017-08-01 |
Omeros Corp |
métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
|
|
EA201590053A1
(ru)
|
2012-06-20 |
2015-08-31 |
Новартис Аг |
Модуляторы пути системы комплемента и их применение
|
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
US9815819B2
(en)
|
2012-06-28 |
2017-11-14 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
EP2867225B1
(en)
|
2012-06-28 |
2017-08-09 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
CN104379579B
(zh)
|
2012-06-28 |
2017-03-08 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
|
WO2014002058A2
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
ES2644700T3
(es)
|
2012-06-28 |
2017-11-30 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
|
|
MX2014015738A
(es)
|
2012-06-28 |
2015-08-06 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la senda del complemento.
|
|
WO2014005150A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
|
|
WO2014002059A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
|
|
CA2882724A1
(en)
|
2012-07-12 |
2014-01-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
CA2881322A1
(en)
|
2012-09-10 |
2014-03-13 |
F. Hoffmann-La Roche Ag |
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
MX366404B
(es)
|
2012-11-15 |
2019-07-08 |
Apellis Pharmaceuticals Inc |
Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
|
|
WO2014078734A2
(en)
|
2012-11-15 |
2014-05-22 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
HK1218300A1
(zh)
|
2013-01-23 |
2017-02-10 |
Musc Foundation For Research Development |
基於天然抗體的靶向結構體及其應用
|
|
US9475806B2
(en)
|
2013-03-14 |
2016-10-25 |
Novartis Ag |
Complement factor B inhibitors and uses there of
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
JP2016169161A
(ja)
|
2013-07-19 |
2016-09-23 |
大日本住友製薬株式会社 |
新規イミダゾピリジン化合物
|
|
SI3011345T1
(sl)
|
2013-08-07 |
2017-12-29 |
Alexion Pharmaceuticals, Inc. |
Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
|
|
US20150104445A1
(en)
|
2013-10-10 |
2015-04-16 |
Viropharma Holdings Limited |
Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
|
|
US9732103B2
(en)
|
2014-02-25 |
2017-08-15 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
|
|
WO2017035348A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of medical disorders
|
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
|
WO2017035411A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of immune and inflammatory disorders
|
|
WO2017035409A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
WO2017035415A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of immune and inflammatory disorders
|
|
WO2017035357A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
|
AR105808A1
(es)
*
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos de amida para el tratamiento de trastornos médicos
|
|
WO2017035418A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for treatment of immune and inflammatory disorders
|
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
|
US10385097B2
(en)
|
2015-08-26 |
2019-08-20 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
|
WO2017035352A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of medical disorders
|
|
WO2017035417A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of immune and inflammatory disorders
|
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
|
WO2017035413A2
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
|
|
WO2017035408A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
AU2016367261A1
(en)
|
2015-12-11 |
2018-07-26 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
JP7339733B2
(ja)
|
2016-01-14 |
2023-09-06 |
ケモセントリックス，インコーポレイティド |
Ｃ３腎症を処置する方法
|
|
WO2017127761A1
(en)
|
2016-01-20 |
2017-07-27 |
Vitrisa Therapeutics, Inc. |
Compositions and methods for inhibiting factor d
|
|
TWI747873B
(zh)
|
2016-02-01 |
2021-12-01 |
美商百歐克斯製藥公司 |
苯并吡唑化合物及其類似物
|
|
SG11201811491YA
(en)
|
2016-06-27 |
2019-01-30 |
Achillion Pharmaceuticals Inc |
Quinazoline and indole compounds to treat medical disorders
|
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
|
EP3589287B1
(en)
|
2017-03-01 |
2022-09-14 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for treatment of medical disorders
|
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
|
CN110603252A
(zh)
|
2017-03-01 |
2019-12-20 |
艾其林医药公司 |
用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
|
|
TW201838974A
(zh)
|
2017-04-19 |
2018-11-01 |
印度商Ｐｉ工業公司 |
具殺菌性質之雜環化合物
|
|
EP3661493A4
(en)
|
2017-08-02 |
2021-04-14 |
Achillion Pharmaceuticals, Inc. |
THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA
|
|
BR112020006692A2
(pt)
|
2017-10-04 |
2020-10-06 |
Alexion Pharmaceuticals, Inc. |
dosagem e administração de anticorpos anti-c5 para o tratamento de pacientes com glomerulonefrite membranoproliferativa
|
|
US11759472B2
(en)
|
2017-11-21 |
2023-09-19 |
Cs Pharmaceuticals Limited |
Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
BR112021018456A2
(pt)
|
2019-03-22 |
2021-11-23 |
Achillion Pharmaceuticals Inc |
Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
|
|
KR20220041846A
(ko)
|
2019-07-31 |
2022-04-01 |
바이오크리스트파마슈티컬즈,인코포레이티드 |
경구 보체 인자 d 억제제에 대한 투약 요법
|
|
IL293588B1
(en)
|
2019-12-04 |
2026-04-01 |
Omeros Corp |
3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof
|